About this Provider
TIA invests in research infrastructure to enable seamless access to expertise and services vital to translate research discoveries into human health impacts. We develop strategic partnerships that are informed by a strong focus on future needs, while working to build a quality workforce – all in support of a vibrant and productive Australian Research and Development ecosystem.
Contact Information
- Translational Research Institute, 37 Kent St, Woolloongabba QLD 4102
National footprint and access
Heading of content section
TIA enables researchers and industry subsidised access to a broad range of expertise across various therapeutic types – Small Molecule Therapeutics, Biologics & Vaccines, RNA Products and Cell & Gene Therapies. Each area is supported by a dedicated broker/facilitator with relevant know-how and experience in areas such as research, clinical trials, translation and manufacturing. These facilitators ensure a smooth process of directing projects to the right facility, advising and mentoring researchers, and supporting collaboration within and between capabilities.
HOW WE CAN HELP
We support your research and innovation by expanding collaborations and access to world-class infrastructures, accelerating the translation of discoveries along the therapeutic development pipeline. We have developed two competitive voucher schemes - Pipeline Accelerator and Technical Feasibility Assessments to further subsidise the cost of access to our facilities.
This Capability enables researchers and industry to identify and translate their biomedical research discoveries, bridging the gap between early-stage development, testing and clinical supply for next-gen therapeutic candidates.
- Antibody discovery and engineering
- Protein production and characteristics
- Process development for biologics
- Antibody-drug conjugates
- Development, manufacturing and regulatory advice
- Establishing quality systems
- GMP/Phase I- enabling manufacture
This Capability supports the development of cutting-edge advanced therapies. Our TGA-licensed cell and gene therapy facilities offer extensive expertise to support your project at any stage of development.
- Viral vector production
- Process and QA development for cell & gene therapies
- Development, manufacturing and regulatory advice
- Establishing quality systems
- GMP/Phase I- enabling manufacture
Our RNA Products Capability enables end-to-end RNA vaccine and therapeutics development within Australia, providing a vibrant and productive pipeline built by onshore researchers – and complementing emerging commercial RNA service providers.
- RNA design and production
- Lipid Nanoparticle formulation
- Development, manufacturing and regulatory advice
- Establishing quality systems
This Capability is a long-established pipeline of complementary capabilities supporting translation of projects from hit identification to preclinical efficacy testing.
- Sample management and logistics
- High throughput screening
- Medicinal chemistry and lead optimisation
- Preclinical efficacy testing
- Development advice
Services
Short explanation on services (optional) Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua
LOREM IPSUM ET DOLOR AMET
ET
LOREM IPSUM ET DOLOR AMET
DOLOR AMET
Equipment
Short explanation on services (optional) Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua
LOREM IPSUM ET DOLOR AMET
ET
LOREM IPSUM ET DOLOR AMET
DOLOR AMET
People
Short explanation on services (optional) Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua
LOREM IPSUM ET DOLOR AMET
ET
LOREM IPSUM ET DOLOR AMET
DOLOR AMET
Fee based:
Access to TIA-funded capabilities and pricing of projects is guided by the following general principles:
In general, facilities will charge based on a three-tier scheme that is widely adopted by NCRIS capabilities. These tiers are:
- Tier 1 (researchers): Charged to public sector researchers, Tier 1 costings should be based on the actual additional costs to the facility to carry out the project, such as consumables and any additional staff (without overheads) that are not NCRIS-funded. The time of NCRIS-funded staff should not be charged to users.
- Tier 2 (spin-outs and SMEs): Charged to companies spun out of public sector research and SMEs which qualify for the R&D tax cash rebate. The charge would be at the marginal rate to carry out the project plus a loading.
- Tier 3 (industry): Charged to companies who do not qualify as Tier 2. The charge would be at the full commercial rate to carry out the project, i.e. the full cost of salaries plus overheads and consumables.
